The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for acti ...

The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved GSK plc’s (NYSE:GSK) Penmenvy (Meningococcal Groups A, B, C, W, and Y ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

"We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by serogroup B. Building on our global leadership ...

Novartis Vaccines and Diagnostics, Inc.), Twinrix (HAV/HBV; GlaxoSmithKline), Engerix-B (HBV; GlaxoSmithKline) and Havrix (HAV; GlaxoSmithKline). All vaccines were administered in accordance with ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.

The FDA has approved Penmenvy, a vaccine for individuals aged 10 to 25, targeting five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which cause invasive meningococcal disease ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug ...

Given the clinical and epidemiologic characteristics of meningococcal disease, vaccination has a major ... 8 Intergroup difference –5% Hepatitis B 10 mIU/mL % of subjects with anti-HBsAg ...